Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care

By afschroeder • July 10, 2025

El Rafei A, Gosch K, Manning ES, Ghajar A, Raghavan S, Maddox TM, Peterson PN, Fleming L, Arnold SV, Chan PS, Greene SJ, Fonarow GC, Jones PG, Allen LA, Hess PL. Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care. JAMA Cardiol. 2025 Jul 9. doi: 10.1001/jamacardio.2025.2145. Epub ahead of print. PMID: 40632519.

Tags: Cardiology/Epi, Publications

Late-in-life treadmill-training mitigates gut microbiome imbalances and cardiovascular disease risk in mice

Cho JM, Park SK, Satheesh Babu AK, Mookherjee S, Hansen M, Petersen C, Zhong Y, Jalili T, Robeson MS, Whankade UD, Anandh Babu PV, Symons[...]

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

New strategies for valve replacement and interventional options in adults with congenital heart disease: new insights from Euro-ACHD 2025

Butera G, Chessa M, Gaio G, Kempny A, Uebing A, Michielon G, Aboulhosn J, Giamberti A, Hoschtitzky A, d'Udekem Y. New strategies for valve replacement[...]